Resources

Newsroom

E

Press Releases

Company Publications

E

FAQs

Frequently Asked Questions

E

Scientific Papers

Related Scientific Publications

Press Releases

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Scientific Papers

Recent knowledge of NFATc4 in oncogenesis and cancer prognosis

By Zhong, QH., Zha, SW., Lau, A.T.Y. et al. Cancer Cell International 22, 212 (2022). https://doi.org/10.1186/s12935-022-02619-6 Abstract Nuclear factor of activated T-cells, cytoplasmic 4 (NFATc4), a transcription factor of NFAT family, which is activated by...

Cholesterol and Hedgehog Signaling: Mutual Regulation and Beyond

By Shouying Xu and Chao Tang Frontiers in Cell and Developmental Biology, volume 10 (2022).  DOI=10.3389/fcell.2022.774291   Abstract The Hedgehog (HH) signaling is one of the key agents that govern the precisely regulated developmental processes of multicellular...

F.A.Q.s

Where is Amira Therapeutics Incorporated?

Amira Therapeutics is a Spanish limited liability company, incorporated on April 23, 2021, in Barcelona, Spain, with VAT number B05407515.

Who is the current owner of Amira Therapeutics?

Amira Therapeutics SL is a company majority-owned by Acondicionamiento Tarrasense, a private technology center founded in 1906 and operating under the Leitat commercial brand. Since 2023, the MGC foundation has been part of the company, owning a minority stake.

How many employees does Amira Therapeutics currently have?

Amira Therapeutics currently has one employee.

Does Amira Therapeutics have any relationship with Amira Pharmaceuticals?

No, Amira Therapeutics and Amira Pharmaceuticals have no relationship. Amira Pharmaceuticals was acquired by Bristol Myers Squibb for $325 million in July 2011, ceasing operations. Until then, Amira Pharmaceuticals was a company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases, while Amira Therapeutics is focused on developing treatments for pediatric cancer.

Stay In Touch